It was a scene few predicted. Mark Cuban, a man who stumped hard for Kamala Harris and once called Donald Trump "unethical," stood shoulder-to-shoulder with the former president at the White House on Monday.
The occasion? A sweeping expansion of TrumpRx, now set to include over 600 generic medications via Cuban’s Cost Plus Drugs company, alongside heavyweights like Amazon Pharmacy and GoodRx. The optics? Unmistakably awkward. This is the same Trump who, just months prior on Truth Social, labeled Cuban "weak and pathetic," a "loser," even "a total non-athlete."
When a reporter, clearly amused, pointed out the remarkable pairing, Trump merely turned to Cuban. "Well, he made a mistake. It was a big mistake," he quipped. Cuban laughed it off. Politics? Not on the agenda, he insisted.
His message to surprised Democrats? "Democrats want cheaper medications, too. The goal is the goal." Simple. Direct. And perhaps, disingenuous for some.
The Core Battle: PBMs and Sky-High Prices
Cuban’s Monday appearance aligns with a years-long mission: dismantling what he calls a rigged system. For years, he has railed against pharmacy benefit managers (PBMs), those opaque intermediaries between manufacturers, insurers, and pharmacies. The three largest PBMs now control approximately 80% of all prescriptions filled in the U.S.
Their original purpose was to negotiate lower prices. But incentives twisted. PBMs often receive rebates based on a drug's list price. They keep a chunk, rather than passing savings directly to patients. This bizarre arrangement often incentivizes them to favor higher-priced drugs. It's a staggering reality: rebates and fees siphoned by PBMs account for 42% of every dollar spent on brand medicines.
Cuban's Cost Plus Drugs aims to rip that system apart. Buy generics directly from manufacturers. Charge acquisition cost plus a modest 15% margin, a small dispensing fee, and shipping. The difference is stark. A cancer drug like Imatinib, costing over $2,000 at conventional pharmacies, lists at roughly $17 on Cost Plus.
Cuban’s actions in the White House on Monday show someone willing to grit his teeth as long as it advances his agenda.
The drug cost crisis in America runs deep. Prescription drugs here cost almost three times more than in other developed nations. The frustration transcends party lines. This unlikely alliance, then, isn't about political camaraderie. It's about a shared target.
Impact and Lingering Questions
For uninsured or underinsured patients, the expanded TrumpRx site promises genuine relief. The ability to comparison-shop across discount providers in one place means modest per-drug savings can compound dramatically over a year.
Yet, the program isn't without its critics. Jeffrey Sonnenfeld of the Yale School of Management, in a February 2026 commentary, argued the program offered no meaningful discounts for those already insured. Many brand-name drugs on TrumpRx, he pointed out, were cheaper through traditional insurance or existing discount programs. And The New York Times found some TrumpRx prices still twice as high as those in other wealthy nations.
The drugs that truly ignite public fury—the outrageously expensive brand-name and specialty medications—remain largely untouched by this expansion. Even as the administration brokered deals with individual manufacturers, at least 350 branded medications saw price increases at the start of 2026. Cuban's model, however, continues to expose the often-absurd chasm between manufacturing cost and pharmacy price.
Cuban, in an email to Fortune, credited the Trump administration for "great people" leading TrumpRx. He also posed the ultimate challenge, back in October 2025: "who has more power and influence over the industry: the PBMs/insurance companies... or the president. That has not been determined yet."
His White House appearance wasn't an endorsement of Trump. It was a calculated move. A tactical embrace. A means to an end. It echoes Michael Jordan's rumored, later confirmed, pragmatism on politics: "Republicans buy sneakers, too."
No comments yet. Be the first to share your thoughts!